Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701760 | 0.85 | HTT (0.62) | LMNAHTTHPGDEGFRCA2 | |
| SCHEMBL17865779 | 0.84 | LMNA (0.58) | LMNAHTTMAPTSIRT2 | |
| SCHEMBL25753420 | 0.84 | CA2 (0.66) | LMNAHTTCA2MEN1CA1 | |
| SCHEMBL3235823 | 0.84 | HTT (0.60) | LMNAHTTHPGDEGFRCA2 | |
| SCHEMBL2282705 | 0.80 | MAOA (0.48) | LMNAHTTMEN1KMT2A | |
| SCHEMBL2522600 | 0.78 | LMNA (0.53) | LMNAHTTKMT2AMAPTSIRT2 | |
| Thiosulfuric Acid SCHEMBL11090486 | 0.76 | EPHX1 (0.60) | LMNAHTTHPGDMEN1CA1 | |
| Thiosulfuric Acid SCHEMBL11090482 | 0.76 | CYP2C9 (0.56) | LMNAHTTHPGDMEN1CA1 | |
| SCHEMBL162828 | 0.76 | TSHR (0.54) | LMNAHTTCA2MEN1CA1 | |
| SCHEMBL13701770 | 0.76 | HDAC2 (0.59) | LMNAHTTHPGDCA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | LMNA 4174/4885HTT 2990/4885HPGD 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.